Overview

Study to Evaluate the Overall Performance of the Zalviso System™ (Sufentanil Sublingual Tablet System) 15 mcg

Status:
Completed
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
Study to evaluate the overall performance of the Zalviso System™ (sufentanil sublingual tablet system) 15 mcg
Phase:
Phase 3
Details
Lead Sponsor:
AcelRx Pharmaceuticals, Inc.
Treatments:
Dsuvia
Sufentanil